Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England.


Journal

Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 10 08 2020
accepted: 01 10 2020
pubmed: 18 10 2020
medline: 25 2 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

People with type 1 diabetes (T1D) face the daily task of implementing self-management strategies to achieve their glycaemic goals. The UK COVID-19 lockdown has had an impact on day-to-day behaviour, which may affect diabetes self-management and outcomes. We assessed whether sensor-based outcomes pre- and during lockdown periods were different in a cohort of glucose sensor users with T1D. Data were collected from Freestyle Libre (FSL) or Dexcom G6 sensor users who remotely shared their data with the diabetes clinic web platform. Sensor metrics according to international consensus were analysed and compared between pre-lockdown period and 2 and 3 weeks into lockdown (periods 1 and 2). Two hundred and sixty-nine T1D patients (baseline HbA1c 57 ± 14 mmol/mol) were identified as FSL (n = 190) or Dexcom G6 (n = 79) users. In patients with sensor use > 70% (N = 223), compared to pre-lockdown period percentage TIR 3.9-10 mM (TIR) significantly increased during period 1 (59.6 ± 18.2 vs. 57.5 ± 17.2%, p = 0.002) and period 2 (59.3 ± 18.3 vs. 57.5 ± 17.2%, p = 0.035). The proportion of patients achieving TIR ≥ 70% increased from 23.3% pre-lockdown to 27.8% in period 1 and 30.5% in period 2. A higher proportion also achieved the recommended time below and above range, and coefficient of variation in periods 1 and 2. Dexcom G6 users had significantly lower % time below range (< 3.9 mM) compared to FSL users during both lockdown periods (period 1: Dexcom G6 vs. FSL: 1.8% vs. 4%; period 2: 1.4% vs. 4%, p < 0.005 for both periods). Sensor-based glycaemic outcomes in people with T1D in the current cohort improved during COVID-19 lockdown, which may be associated with positive changes in self-management strategies. Further work is required to evaluate long-term sustainability and support.

Identifiants

pubmed: 33067723
doi: 10.1007/s00592-020-01614-5
pii: 10.1007/s00592-020-01614-5
pmc: PMC7567414
doi:

Substances chimiques

Blood Glucose 0
Insulin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-237

Références

DiMeglio LA, Evans-Molina C, Oram RA (2018) Type 1 diabetes, Lancet 391(10138):2449–2462. https://doi.org/10.1016/S0140-6736(18)31320-5
doi: 10.1016/S0140-6736(18)31320-5 pubmed: 29916386 pmcid: 29916386
Chatterjee S, Davies MJ (2015) Current management of diabetes mellitus and future directions in care, Postgrad Med J 91(1081):612–621. https://doi.org/10.1136/postgradmedj-2014-133200
doi: 10.1136/postgradmedj-2014-133200 pubmed: 26453594
McCarthy MM, Grey M (2018) Type 1 diabetes self-management from emerging adulthood through older adulthood, Diabetes Care 41(8):1608–1614. https://doi.org/10.2337/dc17-2597
doi: 10.2337/dc17-2597 pubmed: 29802144
van Duinkerken E, Snoek FJ, de Wit M (2019) The cognitive and psychological effects of living with type 1 diabetes: a narrative review, Diabet Med. https://doi.org/10.1111/dme.14216
doi: 10.1111/dme.14216 pubmed: 31850538 pmcid: 7154747
Riazi A, Pickup J, Bradley C (2004) Daily stress and glycaemic control in type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity, Diabetes Res ClinPract 66(3):237–244. https://doi.org/10.1016/j.diabres.2004.04.001
doi: 10.1016/j.diabres.2004.04.001
Trento M et al (2009) Quality of life, coping ability, and metabolic control in patients with type 1 diabetes managed by group care and a carbohydrate counting program, Diabetes Care 32(11):e134. https://doi.org/10.2337/dc09-0903
doi: 10.2337/dc09-0903 pubmed: 19875597
Prime Minister's statement on coronavirus (COVID-19) 2020, https://www.gov.uk/government/speeches/pm-address-to-the-nation-on-coronavirus-23-march-2020
Coronavirus Act 2020, https://www.legislation.gov.uk/ukpga/2020/7/contents/enacted , ed
Evans M, Welsh Z, Ells S, Seibold A (2020) The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies, Diabetes Ther 11(1):83–95. https://doi.org/10.1007/s13300-019-00720-0
doi: 10.1007/s13300-019-00720-0 pubmed: 31673972
Foster NC et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018, Diabetes TechnolTher 21(2):66–72. https://doi.org/10.1089/dia.2018.0384
doi: 10.1089/dia.2018.0384
Aleppo G et al (2017) REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes, Diabetes Care 40(4):538–545. https://doi.org/10.2337/dc16-2482
doi: 10.2337/dc16-2482 pubmed: 28209654 pmcid: 5864100
Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes, Diabetes TechnolTher 19(S3):S25–S37. https://doi.org/10.1089/dia.2017.0035
doi: 10.1089/dia.2017.0035
Battelino T et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range, Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028 pubmed: 31177185 pmcid: 6973648
Nathan DM et al (2008) Translating the A1C assay into estimated average glucose values, Diabetes Care 31(8):1473–1478. https://doi.org/10.2337/dc08-0545
doi: 10.2337/dc08-0545 pubmed: 18540046 pmcid: 2742903
Andrikopoulos S, Johnson G (2020) The Australian response to the COVID-19 pandemic and diabetes-Lessons learned, Diabetes Res ClinPract 165:108246. https://doi.org/10.1016/j.diabres.2020.108246
doi: 10.1016/j.diabres.2020.108246
Verma A, Rajput R, Verma S, Balania VKB, Jangra B (2020) Impact of lockdown in COVID 19 on glycemic control in patients with type 1 diabetes mellitus, Diabetes Metab Syndr 14(5):1213–1216. https://doi.org/10.1016/j.dsx.2020.07.016
doi: 10.1016/j.dsx.2020.07.016 pubmed: 32679527 pmcid: 7357511
Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP (2020) Glycaemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy, Diabetes Ther. 11:1369–1379. https://doi.org/10.1007/s13300-020-00829-7
doi: 10.1007/s13300-020-00829-7
Mesa A et al (2020) The impact of strict COVID-19 lockdown in Spain on glycemic profiles in patients with type 1 diabetes prone to hypoglycemia using standalone continuous glucose monitoring, Diabetes Res ClinPract 167:108354. https://doi.org/10.1016/j.diabres.2020.108354
doi: 10.1016/j.diabres.2020.108354
Dover AR et al (2020) Assessment of the effect of the COVID-19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring, Diabet Med. https://doi.org/10.1111/dme.14374
doi: 10.1111/dme.14374 pubmed: 33128811 pmcid: 7436620
Deshmukh H et al (2020) Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit, Diabetes Care. https://doi.org/10.2337/dc20-0738
doi: 10.2337/dc20-0738 pubmed: 32669277 pmcid: 7440900
Ghosh A, Arora B, Gupta R, Anoop S, Misra A (2020) Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in North India, Diabetes Metab Syndr 14(5):917–920. https://doi.org/10.1016/j.dsx.2020.05.044
doi: 10.1016/j.dsx.2020.05.044 pubmed: 32574982 pmcid: 7265851
Ghosal S, Arora B, Dutta K, Ghosh A, Sinha B, Misra A (2020) Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: a cohort analysis, Diabetes Metab Syndr 14(5):949–952. https://doi.org/10.1016/j.dsx.2020.06.020
doi: 10.1016/j.dsx.2020.06.020 pubmed: 32604013 pmcid: 7303633
https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-full-report , ed
National Institute for Health and Care Excellence, type 1 diabetes in adults: diagnosis and management, https://www.nice.org.uk/guidance/ng17

Auteurs

Joshi Prabhu Navis (J)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.

Lalantha Leelarathna (L)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.
Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester,, M13 9WL, UK.

Womba Mubita (W)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.

Andrea Urwin (A)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.

Martin K Rutter (MK)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.
Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester,, M13 9WL, UK.

Jonathan Schofield (J)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.

Hood Thabit (H)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK. hood.thabit@mft.nhs.uk.
Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester,, M13 9WL, UK. hood.thabit@mft.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH